Boston, MA -- (SBWire) -- 05/04/2013 --BMI View: Cambodia is a market with strong growth potential for pharmaceutical firms, given the many unmet medical needs. However, we highlight that such frontier markets are highly risky, given the lack of proper regulation, extensive bureaucracy and rampant corruption. As a consequence, firms looking to expand in these regions must contend with low or negative sales growth initially.
Headline Expenditure Projections
- Pharmaceuticals: KHR721.1bn (US$170mn) in 2012 to KHR812.5bn (US$190mn) in 2013; +12.7% in local currency terms and +11.2% in US dollar terms. Healthcare: KHR3262.7bn (US$780mn) in 2012 to KHR3582.4bn (US$850mn) in 2013; +9.8% in local currency terms and +8.4% in US dollar terms.
Risk/Reward Rating: Cambodia's Pharmaceutical Risk/Reward Rating (RRR) score for Q213 is unchanged from the previous quarter. This is also the case for all other countries in BMI's proprietary system that ranks pharmaceutical markets according to attractiveness to multinational drugmakers. A minor re-weighting of one of the RRR components is being implemented to improve the tool, and the adjusted scores for all markets will be published in the Q313 updates of the Pharmaceuticals & Healthcare reports. Cambodia has a RRR score of 33.5 out of 100, making it the least attractive pharmaceutical market in Asia Pacific.
View Full Report Details and Table of Contents
Key Trends And Developments.
- In Feburary 2012, In an interview with local media, Phnom Penh Post, Benoit Martineau, head of Cambodia and Laos operations in France-based Sanofi, stated that the firm's plan to expand to all 24 provinces (since January 2013) in Cambodia is to have a 'dedicated local presence, develop products and ensure access for patients'. He maintained that Sanofi is 'very dedicated to the Indochina region', which is unsurprising given that Cambodia, Laos and Vietnam were part of the French colony historically.
- In January 2013, Vabiotech and Inviragen entered into a licensing agreement by which Vabiotech will acquire rights to Inviragen's proprietary Japanese encephalitis (JE) technology to produce a cell-derived vaccine. Under the terms of the agreement, Vabiotech may exclusively develop and commercialise a JE vaccine based on this technology in Vietnam, Cambodia and Myanmar. In exchange, Inviragen will receive certain development-based milestone payments from Vabiotech.
BMI Economic View: The Cambodian economy expanded by 7.3% in 2012 according to a statement made by Prime Minister Hun Sen, driven by agriculture, tourism, garment exports, and construction. The country's current growth boom is attracting interest from luxury brands, and we believe that the mediumterm outlook for the consumer is bright. However, a sharp downturn in loan growth, from its current breakneck pace, should see real GDP growth fall to 6.0% in 2013.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Romania Pharmaceuticals & Healthcare Report Q2 2013
- Nigeria Pharmaceuticals & Healthcare Report Q2 2013
- Croatia Pharmaceuticals & Healthcare Report Q2 2013
- Kuwait Pharmaceuticals & Healthcare Report Q2 2013
- Italy Pharmaceuticals & Healthcare Report Q2 2013
- Poland Pharmaceuticals & Healthcare Report Q2 2013
- Australia Pharmaceuticals & Healthcare Report Q2 2013
- Singapore Pharmaceuticals & Healthcare Report Q2 2013
- Portugal Pharmaceuticals & Healthcare Report Q2 2013
- Central America Pharmaceuticals & Healthcare Report Q2 2013
Report Published: "Cambodia Pharmaceuticals & Healthcare Report Q2 2013"
New Healthcare research report from Business Monitor International is now available from Fast Market Research